The new vials are priced at a 50% or greater discount in comparison to other incretin (GLP-1) medications for obesity, thereby offering a more affordable option for patients
Patients who discontinue semaglutide short-term often experience rapid hunger rebound, as their GLP-1 receptor sensitivity returns to pre-treatment levels
Dominici FP, Argentino DP, Munoz MC, Miquet JG, Sotelo AI, Turyn D
Thomas V Abraham, Research Analyst at Mirae Asset Sharekhan said that the proposed requirement may not necessarily apply to all medicines, but rather to companies that lack a manufacturing footprint in the US similar in structure to the earlier framework applied to branded and patented drugs
Adults with type 2 diabetes prescribed semaglutide were matched, 1:2, with adults prescribed a non-GLP-1 diabetes drug, and adults with overweight or obesity prescribed semaglutide were matched, 1:2, with adults prescribed a non-GLP-1 obesity medication
